Objective: Frontotemporal lobar degeneration (FTLD) is a clinically, genetically, and pathologically heterogeneous disorder. The aim of this study was to compare clinical features and perfusion patterns on SPECT of patients with familial FTLD-TAR DNA binding protein 43 kDa (TDP) and MAPT mutations.
sodic memory deficits in patients with familial FTLD-TDP with and without GRN mutations. 5, 8, 9 Voxel-based morphometry (VBM) on MRI has shown symmetric and predominantly temporofrontal atrophy in MAPT mutations vs asymmetric frontotemporoparietal atrophy in GRN mutations. 10, 11 Functional imaging using SPECT has also revealed asymmetric frontotemporoparietal hypoperfusion in patients with GRN mutations, whereas data on perfusion patterns of MAPT patients are lacking. [12] [13] [14] [15] We aimed to investigate differences in brain perfusion on 99m Tc-HMPAO SPECT scans of patients with familial FTLD-TDP (GRN and UGD) and MAPT mutations by using statistical parametric mapping (SPM8).
METHODS Participants. Patients with FTD were included
in the study since 1994, 5, 16 after referral to the out-clinic department of the Erasmus Medical Center. Detailed clinical history was obtained from spouses and first-degree relatives using a checklist of behavioral and cognitive changes, and motor symptoms. Age at onset was defined as the age at which the first symptoms were observed by a close relative or caregiver. Extrapyramidal and MND signs in neurologic examination were separately noted. Family history, obtained by using a structured questionnaire, was defined as positive if patients had at least one first-degree relative with dementia, parkinsonism, or MND, irrespective of their age at onset. A group of 10 age-and gender-matched controls without neurologic disorders or signs were selected.
Standard protocol approvals, registrations, and patient consents. This study was approved by the Medical Ethical
Committee at the Erasmus MC-University Medical Centre Rotterdam. For each patient, a spouse or first-degree relative of the patient gave written informed consent.
Inclusion criteria. For this study, we included patients with a positive family history, an available 99m Tc-HMPAO SPECT scan, and at least one of the following characteristics: 1) confirmed neuropathologic diagnosis of FTLD in the patient or a first-degree relative, 2) positive DNA screening for MAPT or GRN mutations, 3) being part of a family with FTD-MND and therefore suggestive for FTLD-TDP pathology.
Clinical features. The presence of apathy, disinhibition, obsessive-compulsive behavior, memory deficits, wordfinding difficulties, economy of speech, comprehension deficits and naming deficits, and motor neuron disease was scored as absent or present. Severity of dementia at time of SPECT scan was assessed using the Clinical Dementia Rating scale (CDR). 17 Memory impairment not explained by language deficits included losing objects and forgetting appointments or previous conversations. We scored memory impairment on a 3-point scale: 0, forgetfulness absent or rarely present without interaction of daily life; 1, forgetfulness was sometimes present, interfering mildly with daily life; 2, forgetfulness often to very often present, moderately or severely interacting with daily life. performed in 21 patients and 10 controls. The test battery included  the Mini-Mental State Examination, Trail-Making A and B, Stroop  I, II, and III, the Dutch 15-Word Verbal Learning Test (15-WVLT) , 18 Boston Naming Test, phonological or letter (DAT) fluency, semantic fluency (naming animals and occupations), Clock Drawing long or short, and Orientation for time and place. t Scores were used to correct for age, education, and gender, based on Dutch norms.
Neuropsychological data. Neuropsychological evaluation was
Structural imaging data. The presence and severity of frontal, temporal, and parietal atrophy on structural imaging data (CT or MRI) were reviewed and scored by 2 investigators over the last 15 years as 0) no atrophy, 1) mild atrophy, 2) moderate or severe atrophy. In case of disagreement, a third observer with neuroradiologic expertise was asked for his evaluation.
Genetic screening. Mutation screening of all exons and exonintron regions of MAPT, GRN, and CHMP2B genes were performed in all patients as previously described. 5
Pathology. Brain autopsy was carried out in 12 patients and 2 first-degree relatives included in this study according to the Legal and Ethical Code of Conduct of the Netherlands Brain Bank. The pathology protocols have been described before. 5, 19, 20 A panel of antibodies including AT-8, ubiquitin, TDP-43, and FUS were used for the diagnoses made by the neuropathologist (A.J.M.R.). FTLD-TDP cases were classified as proposed by Sampathu et al. 21 99m Tc-HMPAO SPECT scanning and image processing. Brain perfusion 99m Tc-HMPAO SPECT scans were exclusively performed at the department of nuclear medicine of the Erasmus MC University Medical Centre. Technetium-99mhexamethyl-propylenamine-oxime ( 99m Tc-HMPAO) SPECT scans were acquired on a Prism 3000XP Philips (Picker) 3-headed system, with a fan-beam collimator. Acquisition was performed after injection of 740 MBq 99m Tc-HMPAO while resting in a quiet room. Typically, 2 patients were scheduled at the same time for injection, to ensure that each patient received a freshly prepared injection of radiopharmaceutical. Subsequent imaging took place 5 minutes after injection for the first patient and 30 minutes for the other patient. Duration of scanning was 30 minutes. A 128 ϫ 128 pixel matrix and approximately 7 mm resolution for the Picker camera, as estimated by the manufacturer, was used for image acquisition with 120 projections (40 steps of 3°, and 20 seconds per step) with pixel size and slice thickness of 3.56 mm. Image reconstruction was performed by a ramp-filtered back projection and 3-dimensionally smoothed with a Metz Filter.
After gross manual image reorientation and approximate definition of the image center point, the SPECT scans were spatially processed using Statistical Parametric Mapping SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK) implemented in Matlab 7.4.0 (MathWorks, Natick, MA). SPECT scans were normalized with respect to the Montreal Neurological Institute atlas with a 12-parameter affine transformation followed by nonlinear transformations and a trilinear interpolation. Dimensions of the resulting voxel were 3 ϫ 3 ϫ 3 mm. For every subject, estimation of individual SPECT normalization parameters was constrained by a source weighting image (spm8.a priori{brainmask.nii). This method is used to correct for registering lesioned or abnormal brains. All spatially normalized images were visually checked to make sure that SPECT scans were not misregistrated with the SPM8 SPECT template. Images were then smoothed by a Gaussian filter of 16 mm full width at half maximum (FWHM) that was limited to measured brain tissue. For SPECT data, smoothing to at least twice the FWHM of the imaging system was shown to provide optimal detection sensitivity, 22 and is not unusual in pathologic brains studied with SPECT and PET. 23 Voxel-based image analyses were conducted using SPM8 in the framework of the General Linear Model. 24 The effect of variations in global image intensity was removed by using proportional scaling to the mean global image intensity on an individual basis. We compared relative perfusion using proportional scaling by cerebral global mean values to control for individual variation in 99m TC-HMPAO uptake. The method of using a regional reference 25 was not suitable for our data since we were unable to obtain a reference area where perfusion was relatively preserved in all groups. Group comparisons of spatially normalized and smoothed images were performed on a voxel-byvoxel basis using the "full factorial design" in SPM8. Age and gender were entered as nuisance variables in the design matrix.
We performed the following contrasts: familial FTLD-TDP minus controls; MAPT minus controls; familial FTLD-TDP minus MAPT and inclusively masked ( p Ͻ 0.05) by familial FTLD-TDP minus controls; MAPT minus familial FTLD-TDP and inclusively masked ( p Ͻ 0.05) for MAPT minus controls. Significance level was set at p Ͻ 0.001, uncorrected, and only clusters containing at least 20 contiguous voxels either with or without masking were considered as significant.
Statistical analysis. SPSS 15.0 for Windows (SPSS, Chicago, IL) was used for statistical analysis of clinical and demographic data. Data of age at onset, age at brain SPECT, time between onset and time of SPECT were analyzed using independent-sample t test. The 2 test was used to analyze differences between gender and clinical and structural neuroimaging parameters. The nonparametric Mann-Whitney U test was used to analyze neuropsychological data.
RESULTS Clinical data.
A group of 29 patients was included in this study and consisted of 19 patients with familial FTLD-TDP and 10 patients with MAPT mutations. Of the 19 familial FTLD-TDP patients, 6 had a GRN gene mutation (Ser82ValfsX174 in 5 from one family, Gln125X in one) with pathologic confirmation in one (FTLD-TDP type 3). 21 The other 13 patients came from 10 families: 7 were pathologically diagnosed as FTLD-TDP type 2, 21 4 had a first-degree relative with pathologically confirmed FTLD-TDP, and the remaining 2 patients were part of a large FTD-MND family without pathologic confirmation. Of 3 families, 2 family members were included.
The MAPT mutation group consisted of 10 patients from 2 families (P301L in 8, G272V in 2) and brain specimens were available in 4 cases. There were no patients with FTLD-tau pathology and a positive family history without a MAPT mutation.
Demographic, clinical, and structural imaging data of familial FTLD-TDP, MAPT, and controls are summarized in table 1. Patients with MAPT mutations were younger at time of SPECT scan ( p ϭ 0.039). MND (bulbar in 3) was present in 4 patients of the familial FTLD-TDP cases. Memory impairment was more often present in familial FTLD-TDP ( p ϭ 0.011), whereas obsessive-compulsive behavior ( p ϭ 0.001) and naming deficits ( p Ͻ 0.001) were more often present in MAPT (table 1) .
Neuropsychological data revealed differences on the Boston Naming Test when MAPT was compared to familial FTLD-TDP (p ϭ 0.019), without differences (using t scores) in other cognitive domains. All neuropsychological data and analyses between the 2 distinct patient groups compared to controls are presented in table 2. FTLD-TDP, MAPT, and controls. On SPECT, patients with familial FTLD-TDP compared to controls (p Ͻ 0.001) showed relative hypoperfusion of a variety of areas in frontal, temporal, and parietal lobes ( figure 1 and table e-1 on the Neurology Web site at www.neurology.org). MAPT patients compared to controls showed more temporal and frontal hypoperfusion ( figure 1 and table e-1) .
Perfusion comparisons. Familial
Familial FTLD-TDP directly compared to MAPT showed relative hypoperfusion of the right and left precuneus, right cuneus, precentral gyrus, inferior parietal lobule, inferior frontal and middle frontal gyri, cingulate gyrus, lingual gyrus, and cerebellum. Hypoperfusion of the left hemisphere was found in the cingulate gyrus and middle frontal gyrus (figure 2, table e-2). To confirm that these differences occurred in brain areas where perfusion was indeed lower than in controls, the same analysis was carried out while inclusively masking by the contrast familial FTLD-TDP compared to controls (at p Ͻ 0.05). When masked at this relatively liberal threshold, all regions except the left precuneus and cerebellum remained significant (table e-2).
By comparing MAPT mutations and familial FTLD-TDP directly, relative hypoperfusion was found of the left inferior, middle and superior temporal gyri, right inferior and medial gyri, right rectal gyrus, and left inferior occipital gyrus (figure 2). All temporal and frontal regions remained significant after inclusively masking by the contrast MAPT compared to controls (at p Ͻ 0.05) (table e-2).
Post hoc analyses. Familial FTLD-TDP with UGD, GRN,
MAPT, and controls. To determine whether posterior cortical hypoperfusion in familial FTLD-TDP was not driven by GRN gene mutations, we distinguished between familial FTLD-TDP group with GRN gene mutations (n ϭ 6) and those with UGD (n ϭ 13). This yielded a relative hypoperfusion bifrontally, including precentral gyrus, in right middle temporal lobe, right precuneus, superior parietal lobule, inferior parietal lobule, thalamus, and caudate nucleus in the FTLD-TDP UGD compared to controls (figure 3, table e-3).
Compared to MAPT mutations, FTLD-TDP UGD showed a relative hypoperfusion in the right precentral gyrus, middle frontal gyrus, right and left inferior frontal gyrus, right precuneus, cuneus, and superior parietal lobule ( figure 3, table e-3) .
When familial FTLD-TDP UGD was directly compared to GRN and vice versa, no differences of relative hypoperfusion were found.
Correction for atrophy and GDS. To correct for severity of atrophy and CDR score, we entered these possible confounding covariates in the design matrix. We found that hypoperfusion of the right precuneus, cuneus, cingulate gyrus, inferior parietal lobule, precentral gyrus, inferior and middle frontal gyri remained significant in the familial FTLD-TDP group compared to MAPT group. In the opposite analysis, only relative hypoperfusion of the rectal gyrus was found in the MAPT compared to familial FTLD-TDP, while the relative hypoperfusion of the temporal lobe was not present anymore after accounting for atrophy. In the analyses familial FTLD-TDP UGD compared to MAPT, and familial FTLD-TDP UGD compared to GRN and vice versa, all previous found regions remained hypoperfused.
Correlation between SPECT findings and clinical data.
Memory deficits were significantly more often present in familial FTLD-TDP, whereas obsessivecompulsive behavior and naming deficits were more present in MAPT. We entered the score on memory
Figure 1 Perfusion patterns of familial FTLD-TDP and MAPT compared to controls
Relative hypoperfusion superimposed on a SPM8 canonical single subject template, with a threshold p Ͻ 0.001. deficits, obsessive-compulsive behavior, and naming deficits of the 29 patients in 3 different matrices, with age and gender as nuisance variables. Memory deficits were negatively correlated with relative hypoperfusion of the posterior cingulate and precuneus, right middle frontal gyrus, right inferior parietal lobule, right cerebellum, and right midbrain (figure e-1). This means that a greater memory deficit was associated with a lower perfusion in these areas. Obsessive-compulsive behavior did not correlate with any brain region. Naming deficits were correlated with the left temporal lobe and rectal gyrus.
An analysis with memory as categorical variable between patients with severe and without memory problems revealed relative hypoperfusion in the previous described brain regions, plus the left middle frontal gyrus.
DISCUSSION
The present study comparing familial FTLD-TDP and MAPT has demonstrated relative hypoperfusion in the right frontal and posterior cortical regions in familial FTLD-TDP patients compared to MAPT mutations, whereas relative hypoperfusion was found in the left lateral temporal lobe and medial frontal gyrus in MAPT mutations.
The observation of relative hypoperfusion in the posterior cortical regions, predominantly right-sided, in familial FTLD-TDP (including 6 patients with GRN mutations) is in line with earlier observations in patients with GRN gene mutations, 10, 11, 14 although most of the present patients with familial FTLD-TDP had no GRN mutations. However, parietal lobe and posterior cingulate atrophy on MRI has also been reported in patients with clinical behavioral variant FTD and different underlying pathologies, 26 as well as in patients with FTLD-MND linked to chromosome 9 (family VSM-20). 27 In addition, VBM studies did not find differences between patients with FTLD-tau and FTLD-TDP. 28 -32 Therefore it will be important in future imaging studies to perform group analyses based on clinical, genetic (sporadic and familial), and pathologic status to get explicit information on hypoperfusion and atrophy patterns of FTLD subgroups.
A higher frequency of memory deficits and lower scores on immediate recall memory task were found in familial FTLD-TDP compared to controls, and not compared with MAPT mutations, possibly due to the small sample size of MAPT patients. These memory deficits correlated with precuneus hypoperfusion. This cortical region together with the posterior cingulate is comprised in Papez circuit and related to episodic memory functioning. 33, 34 Atrophy and hypoperfusion of these cortical regions are frequently described in mild cognitive impairment and early-stage Alzheimer disease, 35, 36 and in patients with GRN gene mutations. 10, 11 Our results showed that the occurrence of memory problems also applies for FTLD-TDP with unknown genetic defect. Another novel finding in the present study is the relative hypoperfusion of the precentral gyrus in familial FTLD-TDP compared to controls and MAPT mutations, which might be explained by the frequent occurrence of clinical MND in this form. 37, 38 Sparing of the precentral gyrus in MAPT is in line with the absence of MND in FTLD-tau. 7 It is still unclear why in familial FTLD-MND some family members develop FTD and others MND or both. 19 There might be a certain threshold of precentral hypoperfusion associated with the development of clinical MND, and this hypoperfusion might be an early biomarker in familial FTD-MND.
The finding of predominantly left-sided bifrontotemporal hypoperfusion in MAPT mutations corresponds with the clinical and neuropsychological profile of behavioral variant FTD with naming deficits in these patients. 10, 11, 39 We confirmed in our study the suggestion that MAPT mutations not affecting the splicing of exon 10 have anterolateral temporal and frontal atrophy, as the majority of our patients had a P301L mutation. 39 In contrast to this, MAPT mutations that affect exon 10 splicing and thus influence the alternative splicing of tau premessenger RNA were found to have a more medial temporal gray matter loss, which suggests a possible association between mutation function and atrophy in MAPT. 39 A shortcoming of our study was that patients might have their eyes open or closed during scanning. Despite this, we think that the hypoperfusion of the cuneus and precuneus hypoperfusion in the familial FTLD-TDP group compared to MAPT mutations is a real finding, and presume that eyes were closed or open randomly distributed between groups.
A second shortcoming was the relatively few patients with full neuropsychological data. Therefore, the results of the correlation analyses have to be interpreted with caution. A third shortcoming is that we could not determine brain regions with increased perfusion in our analyses, as the global normalization method we used did not allow increases of perfusion in areas unaffected by pathology. Finally, although SPECT measures may be confounded by atrophy, a voxel-by-voxel correction for atrophy could not be performed due to the different scanners used for structural imaging.
Newer tools in functional brain imaging may help to differentiate FTLD subtypes in the future, espe-cially the development of specific binding tracers in PET. Pittsburgh compound B tracer enables to differentiate between FTLD and AD, 40 but to date there are no specific tracers available to diagnose FTLD or differentiate its pathologic subtypes during life with more certainty. Future studies will focus on the earliest changes in these patients, and which functional molecular networks are affected in the pathogenesis of FTLD-TDP and FTLD-tau. These studies, including PET and fMRI, will hopefully become sensitive enough to detect the earliest changes in presymptomatic mutation carriers to serve as biomarkers for disease progression in future therapeutic studies. Whether the outcomes of familial FTLD cases can be implemented for sporadic FTLD has yet to be elucidated.
